Aldo-Keto Reductases: Multifunctional Proteins as Therapeutic Targets in Diabetes and Inflammatory Disease

被引:27
作者
Chang, Kun-Che [1 ,2 ]
Petrash, J. Mark [1 ,2 ]
机构
[1] Univ Colorado, Dept Ophthalmol, Sch Med, Aurora, CO 80045 USA
[2] Univ Colorado, Dept Pharmaceut Sci, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO 80045 USA
来源
ALCOHOL AND CANCER | 2018年 / 1032卷
关键词
Aldose reductase; Inflammation; Diabetes; Cancer; Inhibitor; Cataract; Retinopathy; Nephropathy; Neuropathy; NF-KAPPA-B; ENDOTOXIN-INDUCED UVEITIS; GLYCATION-END-PRODUCTS; ENDOTHELIAL GROWTH-FACTOR; BLOOD-RETINAL BARRIER; TNF-ALPHA; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; POLYOL PATHWAY; KINASE-C;
D O I
10.1007/978-3-319-98788-0_13
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aldose reductase (AR) is an NADPH-dependent aldo-keto reductase that has been shown to be involved in the pathogenesis of several blinding diseases such as uveitis, diabetic retinopathy (DR) and cataract. However, possible mechanisms linking the action of AR to these diseases are not well understood. As DR and cataract are among the leading causes of blindness in the world, there is an urgent need to explore therapeutic strategies to prevent or delay their onset. Studies with AR inhibitors and gene-targeted mice have demonstrated that the action of AR is also linked to cancer onset and progression. In this review we examine possible mechanisms that relate AR to molecular signaling cascades and thus explain why AR inhibition is an effective strategy against colon cancer as well as diseases of the eye such as uveitis, cataract, and retinopathy.
引用
收藏
页码:173 / 202
页数:30
相关论文
共 50 条
[41]   Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets [J].
Vieira, Marcelo N. N. ;
Lima-Filho, Ricardo A. S. ;
De Felice, Fernanda G. .
NEUROPHARMACOLOGY, 2018, 136 :160-171
[42]   The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10 [J].
Seliger, Jan Moritz ;
Misuri, Livia ;
Maser, Edmund ;
Hintzpeter, Jan .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2018, 33 (01) :607-614
[43]   Evaluation of the prostaglandin F synthase activity of human and bovine aldo-keto reductases: AKR1A1s complement AKR1B1s as potent PGF synthases [J].
Pepin, Nicolas Lacroix ;
Chapdelaine, Pierre ;
Fortier, Michel A. .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2013, 106 :124-132
[44]   Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes [J].
Kimple, Michelle E. ;
Neuman, Joshua C. ;
Linnemann, Amelia K. ;
Casey, Patrick J. .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2014, 46 :e102-e102
[45]   Inflammatory Bowel Disease: Mechanisms, Redox Considerations, and Therapeutic Targets [J].
Biasi, Fiorella ;
Leonarduzzi, Gabriella ;
Oteiza, Patricia I. ;
Poli, Giuseppe .
ANTIOXIDANTS & REDOX SIGNALING, 2013, 19 (14) :1711-1747
[46]   Promising novel therapeutic targets for kidney disease: Emphasis on kidney-specific proteins [J].
Sen, Tathambika Tejeswini ;
Kale, Ajinath ;
Lech, Maciej ;
Anders, Hans-Joachim ;
Gaikwad, Anil Bhanudas .
DRUG DISCOVERY TODAY, 2023, 28 (02) :1-10
[47]   Insulin growth factor binding proteins as therapeutic targets in type 2 diabetes [J].
Hjortebjerg, Rikke ;
Flyvbjerg, Allan ;
Frystyk, Jan .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (02) :209-224
[48]   Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets [J].
Santana, Patricia Teixeira ;
Bittencourt Rosas, Siane Lopes ;
Ribeiro, Beatriz Elias ;
Marinho, Ygor ;
de Souza, Heitor S. P. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
[49]   Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets [J].
Yadav, Vipul ;
Varum, Felipe ;
Bravo, Roberto ;
Furrer, Esther ;
Bojic, Daniela ;
Basit, Abdul W. .
TRANSLATIONAL RESEARCH, 2016, 176 :38-68
[50]   Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease [J].
Alicic, Radica Z. ;
Johnson, Emily J. ;
Tuttle, Katherine R. .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2018, 25 (02) :181-191